undamentalytics Newsletter

Hedge fund

Commodore Capital LP

13F for the quarter to June 30, 2026, filed August 14, 2026 · SEC CIK 1831942

Reported value
$1.7bn
96% in companies we cover
Positions we cover
30
Largest RLAY 13.4%
Copy, a year
+5.6%
S&P 500 +13.8%
Copy Sharpe ratio
0.24
S&P 500 0.68

How copying its 13F would have done

$5.0k$10.0k$20.0k 202120222023202420252026 $20.9k$13.7k
CopyS&P 500 $10,000 copying Commodore Capital LP's filed holdings in companies we cover from February 19, 2021, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).

Biggest drop −56.0% (S&P 500 −23.9%); beta 1.00; alpha −1.8% a year (t = −0.13); last 12 months +51.7% against +12.1%.

Reported value by quarter

Commodore Capital LP: 13F reported value Total value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).
$0 $1B $2B $3B Reported value, 2020-12-31: $183.9M Reported value, 2021-03-31: $251M Reported value, 2021-06-30: $287M Reported value, 2021-09-30: $379.3M Reported value, 2021-12-31: $431.8M Reported value, 2022-03-31: $447.7M Reported value, 2022-06-30: $473M Reported value, 2022-09-30: $621.9M Reported value, 2022-12-31: $663.5M Reported value, 2023-03-31: $656.8M Reported value, 2023-06-30: $889.8M Reported value, 2023-09-30: $855.5M Reported value, 2023-12-31: $1.1B Reported value, 2024-03-31: $1.5B Reported value, 2024-06-30: $1.5B Reported value, 2024-09-30: $1.6B Reported value, 2024-12-31: $1.4B Reported value, 2025-03-31: $1.4B Reported value, 2025-06-30: $1.4B Reported value, 2025-09-30: $2B Reported value, 2025-12-31: $1.5B Reported value, 2026-03-31: $1.7B Reported value, 2026-06-30: $1.7B 2020-12-31 2022-03-31 2023-06-30 2024-09-30 2026-06-30 $1.7B
View chart data
Period Reported value
2020-12-31 $183.9M
2021-03-31 $251M
2021-06-30 $287M
2021-09-30 $379.3M
2021-12-31 $431.8M
2022-03-31 $447.7M
2022-06-30 $473M
2022-09-30 $621.9M
2022-12-31 $663.5M
2023-03-31 $656.8M
2023-06-30 $889.8M
2023-09-30 $855.5M
2023-12-31 $1.1B
2024-03-31 $1.5B
2024-06-30 $1.5B
2024-09-30 $1.6B
2024-12-31 $1.4B
2025-03-31 $1.4B
2025-06-30 $1.4B
2025-09-30 $2B
2025-12-31 $1.5B
2026-03-31 $1.7B
2026-06-30 $1.7B

Holdings and moves

CompanyShare of portfolioValueSharesChange in shares
RLAYRelay Therapeutics, Inc.13.37%$224.5m12.00M−29.4% Reduced
ELVNEnliven Therapeutics, Inc.9.90%$166.2m3.27M0.0%
ALKSAlkermes plc.9.36%$157.2m3.00M−28.6% Reduced
COGTCogent Biosciences, Inc.7.03%$118.0m3.05M+5.6% Added
AMLXAmylyx Pharmaceuticals, Inc.6.04%$101.5m5.65M0.0%
DFTXDefinium Therapeutics, Inc.5.60%$94.1m2.00M0.0%
SYRESpyre Therapeutics, Inc.4.48%$75.2m846.8K−55.7% Reduced
ANROAlto Neuroscience, Inc.4.28%$71.9m2.72M0.0%
TNGXTango Therapeutics, Inc.4.19%$70.3m2.25MNew
EYPTEyepoint, Inc.3.92%$65.8m4.60M+62.8% Added
TYRATyra Biosciences, Inc.3.57%$59.9m1.88M−24.2% Reduced
CLDXCelldex Therapeutics, Inc.2.99%$50.2m1.35M−49.9% Reduced
PHVSPharvaris N.V.2.94%$49.3m1.43M−25.7% Reduced
LBRXLB Pharmaceuticals Inc2.90%$48.7m1.50M0.0%
ASMBAssembly Biosciences, Inc.2.32%$38.9m1.42M+41.5% Added
EDITEditas Medicine, Inc.1.72%$28.8m8.89MNew
KYMRKymera Therapeutics, Inc.1.71%$28.7m250.0K−66.7% Reduced
CATXPerspective Therapeutics, Inc.1.29%$21.6m6.34M0.0%
IPSCCentury Therapeutics, Inc.1.27%$21.3m8.70M0.0%
ZURAZura Bio Ltd1.14%$19.2m3.25M0.0%
AVTXAvalo Therapeutics, Inc.1.12%$18.8m1.02M+110.8% Added
IFRXInflarx N.V.0.97%$16.4m7.30MNew
ANTXAn2 Therapeutics, Inc.0.85%$14.2m2.93M+25.7% Added
SABSSAB Biotherapeutics, Inc.0.67%$11.2m2.87M−34.8% Reduced
IKTInhibikase Therapeutics, Inc.0.65%$11.0m5.40M0.0%
RLMDRelmada Therapeutics, Inc.0.59%$9.9m1.43M+124.8% Added
PEPGPepgen Inc.0.48%$8.1m4.47M0.0%
RACCResearch Alliance Corp III0.32%$5.3m500.0KNew
LONALeonabio, Inc.0.25%$4.3m464.4K0.0%
VTGNVistagen Therapeutics, Inc.0.04%$630,2282.79MNew
CompanyBought (value)Shares
TNGXTango Therapeutics, Inc.$70.3m2.25M
EDITEditas Medicine, Inc.$28.8m8.89M
EYPTEyepoint, Inc.$25.4m1.77M
IFRXInflarx N.V.$16.4m7.30M
ASMBAssembly Biosciences, Inc.$11.4m415.0K
AVTXAvalo Therapeutics, Inc.$9.9m535.3K
COGTCogent Biosciences, Inc.$6.3m162.0K
RLMDRelmada Therapeutics, Inc.$5.5m791.1K
RACCResearch Alliance Corp III$5.3m500.0K
ANTXAn2 Therapeutics, Inc.$2.9m600.0K
VTGNVistagen Therapeutics, Inc.$630,2282.79M

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanySold (value)Shares
SYRESpyre Therapeutics, Inc.−$94.6m−1.07M
RLAYRelay Therapeutics, Inc.−$93.5m−5.00M
ALKSAlkermes plc.−$62.9m−1.20M
KYMRKymera Therapeutics, Inc.−$57.3m−500.0K
ERASErasca, Inc.−$51.4m−3.17M
CLDXCelldex Therapeutics, Inc.−$50.1m−1.35M
XENEXenon Pharmaceuticals Inc.−$48.0m−825.0K
NRIXNurix Therapeutics, Inc.−$35.3m−2.27M
CRVSCorvus Pharmaceuticals, Inc.−$33.0m−2.26M
OCULOcular Therapeutix, Inc−$21.8m−2.58M
TYRATyra Biosciences, Inc.−$19.2m−600.0K
PHVSPharvaris N.V.−$17.1m−494.0K
PALIPalisade BIO, Inc.−$12.6m−7.18M
KPTIKaryopharm Therapeutics Inc.−$10.9m−1.95M
SABSSAB Biotherapeutics, Inc.−$6.0m−1.53M

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanyValue last quarterShares
ERASErasca, Inc.$51.4m3.17M
XENEXenon Pharmaceuticals Inc.$48.0m825.0K
NRIXNurix Therapeutics, Inc.$35.3m2.27M
CRVSCorvus Pharmaceuticals, Inc.$33.0m2.26M
OCULOcular Therapeutix, Inc$21.8m2.58M
PALIPalisade BIO, Inc.$12.6m7.18M
KPTIKaryopharm Therapeutics Inc.$10.9m1.95M
  • Health Care100.0%

Share of the value held in companies we cover, by sector.

PeriodCopy, a yearS&P 500SharpeS&P 500Biggest dropBeta
Whole backtestFebruary 19, 2021 to November 2, 2026+5.6%+13.8%0.240.68−56.0%1.00
Last three yearsNovember 3, 2023 to November 2, 2026+28.2%+21.8%0.721.16−56.0%1.18
Last yearNovember 7, 2025 to November 2, 2026+62.3%+14.2%1.450.84−26.3%0.94

From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.